1月13日,映恩生物科技(上海)有限公司(下称“映恩生物”)与三生制药(01530.HK)宣布就HER2 ADC药物DB-1303签订合作协议。 根据协议,三生制药将获得映恩生物DB-1303多个适应证在中国内地、香港和澳门(下称“合作区域”)的商业化合作权利。映恩生物将获得2500万美元不可退回首付款,并在未来有资格获得至高4200万美元的研发里程碑、以及潜在额外的销售里程碑付款。同时,映恩...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.